Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

Nature Reviews Clinical Oncology

Volumn 6, Issue 6, 2009, Pages 352-366

  Linardou, Helena ^a   Dahabreh, Issa J ^b   Bafaloukos, Dimitrios ^a   Kosmidis, Paris ^c   Murray, Samuel ^a  

^a METROPOLITAN HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c HYGEIA HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; HKI 357; IMATINIB; K RAS PROTEIN; NAVELBINE; PACLITAXEL; PELITINIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR;

CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG PROTEIN BINDING; ETHNIC DIFFERENCE; GENE AMPLIFICATION; GENE FREQUENCY; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SEX DIFFERENCE; SMOKING HABIT; SOMATIC MUTATION; SURVIVAL TIME; DRUG ANTAGONISM; GENETICS; LUNG TUMOR; MUTATION;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 68549140332     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.62     Document Type: Review

References (110)

1. Dassonville, O., Bozec, A., Fischel, J. L. & Milano, G. EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit. Rev. Oncol. Hematol. 62, 53-61 (2007).
2. Hirsch, F. R. & Bunn, P. A. Epidermal growth factor receptor inhibitors in lung cancer: Smaller or larger molecules, selected or unselected populations? J. Clin. Oncol. 23, 9044-9047 (2005).
3. Zhang, W., Gordon, M. & Lenz, H. J. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann. Med. 38, 545-551 (2006).
4. Moosmann, N. & Heinemann, V. Cetuximab in the treatment of metastatic colorectal cancer. Expert Opin. Biol. Ther. 7, 243-256 (2007).
5. Rivera, F., Vega-Villegas, M. E., Lopez-Brea, M. F. & Marquez, R. Current situation of panitumumab, matuzumab, nimotuzumab and zalutuzumab. Acta Oncol. 47, 9-19 (2008).
6. Kris, M. G. et al. efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: A randomized trial. JAMA 290, 2149-2158 (2003).
7. Giaccone, G. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J. Clin. Oncol. 22, 777-784 (2004).
8. Herbst, R. S. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J. Clin. Oncol. 22, 785-794 (2004).
9. Janne, P. A. et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study. Lung Cancer 44, 221-230 (2004).
10. Fukuoka, M. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDeAL 1 trial) corrected. J. Clin. Oncol. 21, 2237-2246 (2003).
11. Thatcher, N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 336, 1527-1537 (2005).
12. Miller, V. A. et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 22, 1103-1109 (2004).
13. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
14. Paez, J. G. et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2, 1497-1500 (2004).
15. Pao, W. & Miller, V. A. epidermal growth factor receptor mutations, small-molecule kinase inhibitors and non-small cell lung cancer: Current knowledge and future directions. J. Clin. Oncol. 23, 2556-2568 (2005).
16. Riely, G. J., Politi, K. A., Miller, V. A. & Pao, W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin. Cancer Res. 12, 7232-7241 (2006).
17. Ciadiello, F. & Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160-1174 (2008).
18. Lievre, A. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374-379 (2008).
19. Linardou, H. et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9, 962-972 (2008).
20. Murray, S. et al. somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: An analytical database. J. Thorac. Oncol. 3, 832-839 (2008).
21. [No authors listed]. Somatic Mutations in Epidermal Growth Factor Receptor Data Base [online], www.somaticmutations-egfr.org (2008).
22. Jorissen, R. N. et al. epidermal growth factor receptor: mechanisms of activation and signaling. Exp. Cell Res. 284, 31-53 (2003).
23. Fontanini, G. et al. evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival. Clin. Cancer Res. 4, 241-249 (1998).
24. Normanno, N. et al. epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366, 2-16 (2006).
25. Nicholson, R. I., Gee, J. M. & Harper, M. E. EGFR and cancer prognosis. Eur. J. Cancer 37, S9-S15 (2001).
26. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signaling network. Nat. Rev. Mol. Cell Biol. 2, 127-137 (2001).
27. Mascaux, C. et al. The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br. J. Cancer 92, 131-139 (2005).
28. Nakamura, H., Kawasaki, N., Taguchi, M. & Kabasawa, K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: A meta-analysis. Thorax 61, 140-145 (2006).
29. Herbst, R. S., Fukuoka, M. & Baselga, J. Gefitinib - a novel targeted approach to treating cancer. Nat. Rev. Cancer 4, 956-965 (2004).
30. Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
31. Cohen, M. H. et al. United states Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 18, 1212-1218 (2004).
32. Hotta, K. et al. relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J. Thorac. Oncol. 2, 402-407 (2007).
33. Gatzemeier, U. et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer; the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25 1545-1552 (2007).
34. Herbst, R. S. et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5892-5899 (2005).
35. Shepherd, F. A. et al. Erlotinib in previously treated non-small cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005).
36. Crino, L. et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell-lung cancer (INVITE): A randomized, phase II study. J. Clin. Oncol. 26, 4253-4260 (2008).
37. Maruyama, R. et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol. 26, 4244-4252 (2008).
38. Kelly, K. et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J. Clin. Oncol. 26, 2450-2456 (2006).
39. Lilenbaum, R. et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J. Clin. Oncol. 26, 863-869 (2008).
40. Cufer, T. et al. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (Iressa) or docetaxel as second-line therapy in patients with advanced (stages IIIB to IV) non-small-cell lung cancer. Anticancer Drugs 17, 401-409 (2006).
41. Chen, Y. M. et al. Phase II randomised study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer 109, 1821-1828 (2007).
42. Kim, E. S. et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372, 1809-1818 (2008).
43. Johnson, J. R. et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. Clin. Cancer Res. 11, 6414-6421 (2005).
44. Stinchcombe, T. E. & Socinski, M. A. Gefitinib in advanced non-small cell lung cancer: Does it deserve a second chance? Oncologist 13, 933-944 (2008).
45. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004).
46. Marchetti, A. et al. EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23, 857-865 (2005).
47. Shigematsu, H. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97, 339-346 (2005).
48. Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, 57-61 (2005).
49. Chan, S. K., Gullick, W. T. & Hill, M. E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy. Eur. J. Cancer 42, 17-23 (2006).
50. Gu, D. et al. Database of somatic mutations in EGFR with analysis revealing indel hotspots but no smoking-associated signature. Hum. Mutat. 28, 1-11 (2007).
51. Wu, Y. L. et al. epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: A meta-analysis based on updated individual patient data from six medical centers in mainland China. J. Thorac. Oncol. 2 430-439 (2007).
52. Costa, D. B., Kobayashi, s., Tenen, D. G. & Huberman, M. S. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR mutant non-small cell lung cancers. Lung Cancer 58, 95-103 (2007).
53. van Zandwijk, N. et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: Retro- and prospective observations in non-small-cell lung cancer. Ann. Oncol. 18, 99-103 (2007).
54. Cappuzzo, F. et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: The ONCOBeLL trial. J. Clin. Oncol. 25, 2248-2255 (2007).
55. Howard, L. et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J. Clin. Oncol. 24, 1807-1813 (2006).
56. Miller, V. A. et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J. Clin. Oncol. 26, 1472-1478 (2008).
57. Sequist, L. V. et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 26, 2442-2449 (2008).
58. Tamura, K. et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: Results of the west Japan Thoracic Oncology Group trial (WJTOG0403). Br. J. Cancer 98, 907-914 (2008).
59. Sunaga, N. et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 56, 383-389 (2007).
60. Inoue, A. et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. 24, 3340-3346 (2006).
61. Asahina, H. et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br. J. Cancer 95, 998-1004 (2006).
62. Sutani, A. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br. J. Cancer 95 1483-1469 (2006).
63. Yoshida, K. et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J. Thorac. Oncol. 2, 22-28 (2007).
64. Sugio, K. et al. Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer doi:10.1016/j.lungcan.2008.09.010 (2008).
65. Carey, K. D. et al. Kinetic analysis of epidermal growth factor receptor somatic mutant protein shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66, 8163-8171 (2006).
66. Sordella, R., Bell, D. W., Haber, D. A. & settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167 (2004).
67. Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. epidermal growth factor receptor mutations in lung cancer. Nat. Rev. 7 169-181 (2007).
68. Politi, K. et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20 1496-1510 (2006).
69. Weinstein, I. B. Cancer. Addiction to oncogenes - the Achilles heel of cancer. Science 297, 63-64 (2002).
70. Carey, K. D. et al. Kinetic analysis of epidermal growth factor receptor somatic mutant protein shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66, 8163-8171 (2006).
71. Ono, M. & Kuwano, M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin. Cancer Res. 12, 7242-7251 (2006).
72. Ramirez, P. & Di Persio, J. F. Therapy options in imatinib failures. Oncologist 13, 424-434 (2008).
73. Pallis, A. G. et al. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br. J. Cancer 97, 1560-1566 (2007).
74. Marchetti, A., Felicioni, L. & Buttitta, F. Assessing EGFR mutations. N. Engl. J. Med. 345, 526-527 (2006).
75. Paz-Ares, L. et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) [Abstract 7020]. J. Clin. Oncol. 24, 18s (2006).
76. Dahabreh, I. J., Linardou, H., Siannis, F., Fountzilas, G. & Murray, S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials. Oncologist 13, 620-630 (2008).
77. Moroni, M. et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical responses to anti-EGFR treatment in colorectal cancer: A cohort study. Lancet Oncol. 6, 279-286 (2005).
78. Mitsudomi, T. et al. Mutation of the epidermal growth factor gene predicts prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23, 2513-2520 (2005).
79. Cappuzzo, F. et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl Cancer Inst. 97, 643-655 (2005).
80. Bell, D. W. et al. epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23, 8081-8092 (2005).
81. Tsao, M. S. et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144 (2005).
82. Li, A. R. et al. EGFR mutations in lung adenocarcinomas: Clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J. Mol. Diagn. 10, 242-248 (2008).
83. Pham, D. et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J. Clin. Oncol. 24, 1700-1704 (2006).
84. Sequist, L. et al. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin. Cancer Res. 12 (Pt 2), 4403s-4408s (2006).
85. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352 786-792 (2005).
86. Toyooka, S. et al. EGFR mutation and response of lung cancer to gefitinib. N. Engl. J. Med. 352, 2136 (2005).
87. Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366-377 (2008).
88. Inukai, M. et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 66, 7854-7858 (2006).
89. Balak, M. N. et al. Novel D761Y and common secondary T790M mutations in EGFR-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12, 6494-6501 (2006).
90. Wu, J. Y. et al. Lung cancer with epidermal growth factor exon 20 mutations is associated with poor gefitinib treatment response. Clin. Cancer Res. 14, 4877-4882 (2008).
91. Shigematsu, H. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97, 339-346 (2005).
92. Greulich, H. et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2, e313 (2005).
93. Eberhard, D. A. et al. Mutations in the epidermal growth factor receptor and KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909 (2005).
94. Endoh, H., Yatabe, Y., Kosaka, K., Kuwano, H. & Mitsudomi, T. PTeN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J. Thorac. Oncol. 1, 629-634 (2006).
95. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
96. Bean, J. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci. USA 104, 20932-20937 (2007).
97. Hirsch, F. R. et al. Molecular analysis of EGFR gene copy number, EGFR expression, and Akt activation status in advanced non-small cell lung cancer (aNSCLC) treated with gefitinib or placebo (ISEL trial). Clin. Cancer Res. 24, 9031s (2005).
98. Cappuzzo, F. et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small cell lung cancer patients. J. Clin. Oncol. 1, 5007-5018 (2005).
99. Engelman, J. A. et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl Acad. Sci. USA 102, 3788-3793 (2005).
100. Kwak, E. L. et al. irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl Acad. Sci. USA 102, 7665-7670 (2005).
101. Riely, G. J. second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J. Thorac. Oncol. 3 (Suppl. 2), s146-s149 (2008).
102. Ciardiello, F. et al. inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 7, 1459-1465 (2001).
103. Morelli, M. P. et al. Sequence-dependent antiproliferative effects of cytostatic drugs and epidermal growth factor receptor inhibitors. Ann. Oncol. 16 (Suppl. 4), iv61-iv68 (2005).
104. [No authors listed] TKI-CAN. Tyrosine Kinase Inhibitor Consortium Against Non-Small-Cell Lung Cancer [online] www.tki-can.info (2008).
105. Shepherd, F. A. Molecular selection of patients for first-line treatment of advanced non-small cell lung cancer with epidermal growth factor inhibitors: Not quite ready for prime time. J. Clin. Oncol. 26 2426-2427 (2008).
106. Rosell, R., Taron, M., Reguart, N., Isla, D. & Moran, T. Epidermal growth factor receptor activation: How exon 19 and 21 mutations changed our understanding of the pathway. Clin. Cancer Res. 12, 7222-7231 (2006).
107. Altman, D. G. & Royston, P. What do we mean by validating a prognostic model? Stat. Med. 19, 453-473 (2000).
108. Sequist, L. V., Bell, D. W., Lynch, T. J. & Haber, D. A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 27, 587-595 (2007).
109. Burkhard, B., Meyer-Staeckling, S., Schmidt, H., Agelopoulos, K. & Buerger, H. Mechanisms of EGFR gene transcription modulation: relationship to cancer risk and therapy response. Clin. Cancer Res. 12, 7252-7260 (2006).
110. Ioannidis, J. P. & Trikalinos, T. A. early extreme contradictory estimates may appear in published research: The proteus phenomenon in molecular genetics research and randomized trials. J. Clin. Epidemiol. 58, 543-549 (2005).